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Regulatoryfactorsinnormalandmalignantmelanocytes
R. Halaban', Y. Funasaka', J. Cowan2 & D. Birnbaum3
'Department of Dermatology, Yale University School of
Medicine, New Haven, Connecticut, USA; 2Department of
Radiation Oncology, University of Chicago Medical Center,
Chicago, Illinois, USA; 3Institute Paoli-Calmettes, Marseille,
France.
Melanomas are highly variable with respect to aberrant gene
expression and chromosomal lesions but share a common
characteristic of an acquired independence from environ-
mental growth factors that are needed for proliferation of
normal melanocytes. This autonomy is achieved in part via
the endogenous production of basic fibroblast growth factor
(bFGF), which is not expressed in normal melanocytes.
Other melanocyte mitogens such as acidic FGF (aFGF),
K-FGF/hst, FGF-5 and FGF-6, are not expressed in
melanomas, in spite of the presence of amplified K-FGF/int-2
linked genes in one out of ten melanomas. These other
mitogens may however, have a role in promoting the growth
of melanomas at site of metastasis since some of them are
known to be produced in normal tissues. The bFGF receptor
is a tyrosine protein kinase that is constitutively active in
melanomas. Blocking of the tyrosine-kinase activity by
antagonists, antibodies or low molecular weight inhibitors,
retards melanoma growth in culture, suggesting new direc-
tions for drug design for the clinical management of meta-
static melanomas.
Mesenchymal interactions withhumanmelanomacellsaffecting
tumourcellgrowth are afunction oftumourprogression
I. Cornil & R.S. Kerbel
Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, 600
University Avenue, Toronto, Ontario MSG IX5, Canada.
It is known that the ability of tumour cells to grow locally
and metastasise can be affected by the presence of adjacent
normal tissues and cells, such as fibroblasts. However the
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comparative influence of such cell interactions on tumour
behaviour has not been thoroughly investigated from the
perspective of diffeent stages of tumour progression.
Specifically, we wished to determine whether the nature and
effects of such cell interactions would vary between
metastatically-competent vs incompetent tumour cell popula-
tions. To address this question we assessed the influence of
normal dermal fibroblasts on the growth of human
melanoma cells obtained from different stages of tumour
progression. We found that the in vitro growth of most (four
out of five) melanoma cell lines derived from early stage
metastatically-incompetent primary lesions is repressed by
coculture with normal dermal fibroblasts, suggesting that
negative homeostatic growth controls are still operative on
melanoma cells from early stages of disease. On the other
hand, nine out of 11 melanoma cell lines derived from
advanced metastatically competent primary lesions, or from
distant metastases, were found to be growth stimulated in the
presence of dermal fibroblasts. This discriminatory fibroblas-
tic influence is mediated by soluble inhibitory and
stimulatory growth factor(s) whose nature could not be
identified by using neutralising antibodies directed against
known growth factors. Taken together, these results indicate
that fibroblast-derived signals can have antithetical effects on
metastatic vs metastatically-incompetent tumour subpopula-
tions. This resultant conversion in responsiveness may confer
upon metastatic cells a growth advantage allowing them to
escape local growth controls both locally and at distant
ectopic tissue sites.
Changesin antigenexpressionduringmelanomaprogression
M. Herlyn&I. Juhasz
The Wistar Institute of Anatomy and Biology, Philadelphia,
Pennsylvania 19104, USA.
Expression of antigenic markers on different cell types of the
melanocytic lineage changes with tumour progression. Few
antigens have been identified with monoclonal antibodies
that define only normal and non-malignant melanocytic cells.
These include the adenosine deaminase binding protein and a
140,000 dalton glycoprotein. Higher expression of ganglio-
sides GD3 and acetylated GD3, cell-cell interacting chond-
roitin sulfate proteoglycan gp34, and HLA-DR were found
on mature nevus cells vs normal melanocytes. Differences
between mature and dysplastic nevi were not significant nor
were those between advanced (vertical growth phase [VGP])
primary and metastatic melanomas. Differences were most
notable between non-invasive (radial growth phase [RGP])
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and invasive (VGP) primary melanomas. When the results on
dysplastic nevi and RGP primary melanomas were combined
and compared with those of VGP primary melanomas and
metastases, several antigens were expressed in significantly
higher numbers on more malignant cells. These include the
vitronectin receptor, the receptors for EGF and transferrin,
the extracellular matrix protein tenascin, ganglioside GD2
and the cell-cell adhesion molecules ICAM-1 and MUC18.
These results indicate that extensive structural changes occur
in cells with tumour progression.
Denovoexpressionofcell adhesion moleculescorrelates withthe
development ofmetastatic potential incutaneous melanoma
J.P. Johnson, J.M. Lehmann, B.G. Stade & G. Riethmuller
Institute for Immunology, University ofMunich, Goethestrasse
31, 8000 Munich 2, Germany.
Metastatic potential in cutaneous melanoma first appears
with the onset of the vertical growth phase and the proba-
bility of developing metastatic disease increases with increas-
ing vertical thickness of the tumour. Searching for changes in
gene expression which correlate with increasing tUmour
thickness, may lead to the identification of molecules which
are involved in the metastatic process. We isolated two
monoclonal antibodies which reacted with more than 70% of
thick primary melanomas, but which showed no reactivity
with melanocytic nevi or with thin radial growth phase
primary tumours. The cDNAs encoding these antigens were
obtained by antibody screening of expression libraries.
Sequencing of the cDNA clones revealed that one antigen
was the intercellular adhesion molecule ICAM-1 which
mediates adhesion with leukocytes. The second antigen,
MUC18, is a novel member of the immunoglobulin super-
family and has structural characteristics of a cell adhesion
molecule. Alterations in intercellular adhesion are thought to
play a major role in the metastatic process and the role of
these two molecules in the interaction ofmelanoma cells with
other cells and tissues is being examined.
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Thecomparative biology oftumourprogression
W.H. ClarkJr
Pigmented Lesion Study Group, 217 Clinical Research Build-
ings, 422 Curle Boulevard, University of Pennsylvania,
Philadelphia, Pennsylvania 19104, USA:
Induction of a neoplastic system produces focal, proliferative
lesions that are benign at the outset. Tumour progression is a
sequence ofchanges occurring within the proliferative lesions
of neoplasia resulting in a series of qualitatively different
lesions; lesions that may progress from benign to malignant
to increasing malignancy. Tumour progression is the biologic
phenomenon linking the seemingly heterogeneous lesions of
neoplasia into a single disease entity. Cancer is derived
through tumour progression not by transformation of a
putatively normal cell. Photographs of pigmented lesions of
all patients seen over 14 years, histologic study of lesions
from the same cohort of patients, and the in vitro study of
cells derived from representative lesions of these patients
have permitted us to define the lesions of tumour progres-
sion. Class I lesions are precursor lesions showing temporarily
restricted growth confined to the tissue compartment of
origin. Early Class I lesions are benign tumours that tend to
differentiate and disappear. Later Class I lesions show aber-
rant differentiation and still later ones show dysplasia and
may occasionally progress to Class II. Class II lesions do not
metastasise and are intermediate between the precursor
lesions of Class I and overt, invasive primary cancer, Class
III. Neoplastic cell growth in Class II is temporarily unre-
stricted, but still confined to the original tissue compartment;
invasion is not manifest. Class III lesions are invasive
primary cancers. Early on such cancers lack capacity for
metastasis, but through progression acquire metastatic com-
petence. In melanoma, metastases are predicted by the nature
of at least six attributes: mitotic rate mm-2; quantity of
tumour infiltrating lymphocytes; thickness; anatomic site of
the primary; sex of the patient, and the presence ofhistologic
regression. Class IV lesions are metastases. The study of
cutaneous squamous cell carcinoma, colonic carcinoma and
hepatocellular carcinoma has shown diverse neoplastic
systems to be similar even when inductive mechanisms are
apparently quite different.
Aetiology andpreventionofmelanoma
R.M. MacKie
Dermatology Department, University of Glasgow, Glasgow
G128QQ, UK.
Detailed epidemiological and case control studies from Aust-
ralia, Western Canada, Denmark and Scotland strongly
implicate exposure to ultraviolet radiation as a major aetio-
logical factor in cutaneous malignant melanoma. For
superficial spreading and nodular melanomas short episodes
of intense UV exposure such as those encountered on con-
tinental holidays appear of particular importance, while for
lentigo maligna melanoma total lifetime sun exposure
appears more important. A large number of case control
studies in the past 5 years have identified total number of
melanocytic naevi as the strongest risk factor for melanoma,
and there are at present several studies investigating the
aetiology of naevi. In Scotland the four strongest risk factors
in a large case control study are total number of naevi,
presence of freckles, number of naevi of diameter 5 mm or
greater and episodes of severe sunburn. Both primary and
secondary prevention of melanoma are theoretically feasible.
Secondary prevention involves public education to encourage
referral and treatment of melanomas when they are in an
earlier growth phase and thinner tumours. A recent Scottish
study has recorded a statistically significant drop in
melanoma Breslow thickness over a period of public educa-
tion. The main thrust of primary prevention would appear to
be encouraging a more cautious attitude to sun exposure and
prevention of UV-induced damage. In Australia active public
education has resulted in striking behavioural change. It will
take some years to evaluate whether or not this is associated
with a fall in melanoma incidence and, more important,
mortality.
Chemotherapy formelanoma
M.E. Gore
Melanoma Unit, Royal Marsden Hospital, Fulham Road,
London, UK.
The results of chemotherapy for advanced melanoma are
disappointing. The most active single agents are: dacarbazine
(DTIC) which has a response rate of 24%, and vindesine,
cisplatin and nitrosoureas which all have response rates of
about 15%. Response durations are short, 4-6 months and
complete remissions to single agent therapy rare. Ran-
domised studies of DTIC - containing combinations or com-
binations without DTIC do not suggest any advantage over
single agent DTIC. Response rates of almost 50% have been
reported in some more recent phase II studies using DTIC -
or cisplatin - containing regimens, but randomised trials are
needed to properly evaluate these new schedules. Recently,830 JOINT WINTER MEETING REPORT
there has been considerable interest in the observation that
when tamoxifen is added to a combination of cisplatin,
DTIC and BCNU the response rate is doubled. One of the
major difficulties in interpreting the results of chemotherapy
in melanoma is that different sites of disease show different
rates of response: lymph node, skin or soft tissue metastases
are the most responsive (34%) followed by the lungs (16%)
and finally the brain and liver (8%). The same regimen may
therefore have a very different response rate depending on
the proportion of patients that have a visceral element to
their metastatic disease. There is no evidence that
chemotherapy is of any benefit when given in the adjuvant
setting to patients at high risk from relapse from melanoma.
Future studies are likely to involve the integration of
chemotherapy with biological response modifiers such as
interferon and interleukin-2 and these approaches are already
showing promise.
Recombinationinterleukin 2(IL-2)inadvancedmalignant
melanoma
N. Thatcher
Department of Medical Oncology, Christie Hospital,
Manchester M20 9BX, UK.
IL-2 a glycoprotein secreted by activated T lymphocytes is a
growth factor for antigen stimulated T cells. IL-2 also
stimulates the production of other cytokines which may
themselves have antitumour activity. The tumourcidal
activity of natural killer (NK) cells and cytotoxic T lympho-
cytes is also enhanced by IL-2 and these lymphokine
activated killer (LAK) cells are capable oflysing fresh human
tumour cells. Rosenberg and colleagues have recently
updated the original 1985 study of IL-2 + LAK cell
(generated ex vivo) therapy. An objective response rate of
21% in 48 patients with advanced melanoma was reported
with 5-10% having durable remissions for up to 4 years
(Ann. Surg., 210, 474, 1989). Subsequent confirmation of
antimelanoma activity came from the IL-2/LAK extramural
working group (Dutcher et al., J. Clin. Oncol., 7, 477, 1989).
These early studies used the maximum tolerated doses of
IL-2 and were associated with severe toxicity in some
patients requiring ICU facilities. The use of continuous
infusion or intermittent i.v. bolus IL-2 therapy has allowed
similar total doses to be delivered as by the Rosenberg group
but with much less toxicity and similar antimelanoma activity
(West et al., New Engl. J. Med., 316, 898, 1987; Thatcher et
al., Br. J. Cancer., 60, 770, 1989). IL-2 alone may indeed be
as effective as the IL-2 + LAK cell combination and avoids
the considerable logistic difficulties of LAK cell generation.
IL-2 has also been used in combination with chemotherapy
e.g. cyclophosphamide at low dose as an immunomodulating
agent or with DTIC as a cytotoxic agent. Other approaches
have included the expansion of tumour infiltrating lympho-
cytes (TIL) and of more general interest IL-2 with
Interferons. The latter combination may provide greater
antimelanoma activity than either agent alone. Recently the
feasibility of out patient therapy for this combination of
cytokines has been established and little toxicity has been
observed. IL-2 is therefore an important addition to the
treatment of advanced melanoma and has established
immunotherapy as the fourth modality of cancer therapy.
Activespecificimmunotherapy withaliogeneicmelanoma lysates
M.S. Mitchell
Departments of Medicine and Microbiology, University of
Southern California Cancer Center, Los Angeles, California
90033, USA.
In order to validate the efficacy of our materials prior to
treating minimal residual disease, we have treated patients
with measurable disseminated melanoma, with active specific
immunotherapy. Mechanical lysates of two cell lines of
melanoma were combined with the adjuvant DETOX and
injected s.c. on weeks 1, 2, 3, 4 and 6 into nearly 100 patients
in six separate trials. A major response. rate of 20% has been
achieved, with 5% complete remissions. Another 10% of the
patients have had minor responses: (25-50% shrinkage for
>4 week or >50% shrinkage lasting <4 weeks). Complete
or partial remissions have been seen in subcutaneous sites,
lymph nodes, lungs, and small intestine, with 33% shrinkage
of a large liver nodule in one patient and disappearance of a
1.5 cm liver nodule (cyst?) in another. Thus far, seven
patients have had continuing responses lasting 1 to
>4 years, on 'maintenance' immunotherapy. One patient
with a primary ocular melanoma has also been treated. The
lesion shrank from 4.2 to 2.3 mm within 6 weeks and has
remained that size for >6 months. No toxicity was
associated with this treatment, except local granulomas in
patients receiving 15 or more injections. The frequency of
cytolytic T cell precursors has been increased in responders,
whereas patients without an increase invariably have failed to
respond. Both CD4 + and CD8 + cytolytic T cell clones
have been grown from treated patients. Most CD4 + CTL
were not Class II MHC restricted, reacting broadly against
melanoma cell lines but not other types of tumour. Several of
the clones in fact reacted against melanomas lacking Class II
MHC antigens. Some CD8 + CTL were self-MHC restricted,
as in mice, but more usually recognised melanoma antigens
presented by the HLA-A2 molecule on several cell lines. The
HLA phenotypes of responders and non-responders were
compared. Significant correlations have been found between
clinical response and the presence of HLA-A2 together with
either B44 or DR4. Allogeneic lysates and DETOX may have
stimulated additional T-helper cells and augmented the re-
sponse to autologous melanoma-associated antigens, leading
to responses in genetically favourable individuals. A large-
scale clinical trial randomising patients to treatment with
melanoma theraccine or observation will now be performed
in the setting of minimal residual disease.
Prognostic factorsinbladdercancer
C. Fisher
Department of Histopathology, Royal Marsden Hospital,
Fulham Road, London SW36JJ, UK.
Transitional cell carcinomas account for about 95% of blad-
der carcinomas in the UK. They are separable into subtypes
with different behaviour and management: carcinoma in situ
(CIS), superficial disease and muscle-invasive carcinoma. A
principal prognostic factor is T stage, for which the preferred
staging system remains the the- UICC 3rd Edition (1978)
rather than the 4th Edition (1987). The so-called muscularis
mucosae may form a prognostic subdividing line within TI
tumours. For superficial tumours, factors reported as predis-
posing to recurrence or progression include number and size
of tumours, grade, coexistent CIS, cell surface blood group
antigen status, aneuploidy, EGF receptor expression, and
findings at 3 month follow up cystoscopy. Behaviour of
muscle-invasive tumours may be influenced by tumour size,
grade, pattern of invasion, lymphatic invasion and lymph
nodal status. The presence of squamous metaplasia may
affect response to radiotherapy. For other types of bladder
carcinoma the prognosis is related principally to stage at
presentation (squamous cell or adenocarcinoma), or to histo-
logical subtype (small cell).JOINT WINTER MEETING REPORT 831
Molecularbiology ofbladder cancer
M.A. Knowles, J.P. Cairns, L.M. Coombs & A.J. Proctor
Marie Curie Research Institute, The Chart, Oxted, Surrey
RH8OTL, UK.
A number of genetic changes are required for epithelial
transformation. For several tumour types including colon,
breast and lung, the identity of certain of the genes involved
is now known, some of the molecular mechanisms involved
in the generation of the transformed phenotype have been
elucidated and clinical correlates with these molecular
changes have been identified. Some changes are shared by
several tumour types whilst others appear to be cell type
specific. Recently, a number of frequent molecular alterations
have been identified in transitional cell tumours. We have
shown that the proto-oncogene HER2 is amplified and over-
expressed in many tumours and that this shows a strong
correlation with tumour grade. Amplification of HER2 was
detected in 2% ofgrade 1, 16% of grade 2 and 46% ofgrade
3 tumours. The protein product of this gene can be detected
by immunohistochemistry only at the luminal surface of
mature superficial cells in the normal urothelium but shows a
widespread distribution in some tumours. We have also
identified a region of amplified DNA on chromosome 1q13
in 20% of tumours. This region contains the oncogenes INT2
and HST, members of the FGF family of genes and the
BCL1 locus which is frequently involved in breakpoints in B
cell tumours. The identity of the target gene within this
amplicon is not known. Since expression of INT2 and HST
are not detected in tumours with gene amplification, it is
postulated that an unknown gene within this region has yet
to be identified. These amplifications show no correlation
with tumour grade, nor with HER2 amplification status. A
third genetic change recently identified in this laboratory
concerns the retinoblastoma susceptibility gene RBI. In 30%
of bladder tumours we have detected loss or re-arrangement
of one allele of the gene. These changes appear to involve
predominantly tumours of high grade and stage. Our
findings, together with those from other laboratories includ-
ing the presence of RAS mutations, p53 mutations, over-
expression of the epidermal growth factor receptor and the
identification of sites of allelic loss on chromosomes 9q, 1lp
and 17p now provide the basis for a classification of transi-
tional cell tumours according to the genetic lesions they
contain. The divergent clinical phenotype of bladder tumours
is well known. It may be postulated that the number, com-
bination and/or timing of such molecular events determines
the natural history of the disease and the phenotype of the
tumours which develop. The identification of these lesions in
bladder tumours should therefore present powerful diagnostic
and prognostic tools and may provide the key to progress in
therapy.
Intravesical Bacillus calmette-guerin forcarcinoma in situofthe
urinary bladder
D.M.A. Wallace
The Queen Elizabeth Hospital, Birmingham, UK.
BCG was first instilled into the bladder in the early 1970's as
empirical immunotherapy for superficial bladder tumours. It
has since been shown to be as effective as intravesical
chemotherapy in the treatment of superficial tumours and in
prophylaxsis against recurrences. Some studies have also
shown complete response rates for carcinoma in situ of the
bladder (CIS) of up to 90% which have been sustained. CIS
of the bladder remains a disease that is hard to define and
quantify. Few randomised trials of BCG in CIS of the blad-
der are available. The side effects of BCG can be serious and
sometimes fatal. Several different strains are in use at present
and a recent MRC Study suggests that there may be
differences in side effects and in efficacy which will require a
larger study to demonstrate if these are significant. The exact
mode of action of BCG is not clear and the optimum treat-
ment schedule for each strain is yet to be established. Efforts
must continue to determine the appropriate end point of
treatment in order to reduce the local and systemic toxicity
of intravesical BCG.
Theroleofradiotherapy inthetreatmentofbladdercancer
J.T. Roberts
Regional Radiotherapy Centre, Newcastle General Hospital,
Newcastle upon Tyne, UK.
Modern megavoltage radiotherapy can cure some patients
with muscle-invasive bladder cancer, producing an overall
5-year survival of 17-39% in a number of series, with
preservation of a functioning bladder. The identification of
appropriate prognostic indicators such as patholgoical sub-
types, radiographic appearance, clinical stage and radiation
responsiveness may allow the selection of those most likely to
benefit from radical radiotherapy. Radiotherapy alone pro-
duces immediate complete response rates of approximately
50% in the bladder. The observation, by several workers, of
immediate complete response rates of 70% or more following
combined therapy with radiation and cisplatin-based chemo-
therapy regimes has led to the instigation of a number of
controlled trials of combination therapy. Recently published
retrospective studies have suggested that radical external
beam irradiation may have a role in the management of high
grade superficial bladder cancer and the Medical Research
Council are proposing a randomised study to assess this role.
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Bladdercancer: theintegrationofsurgerywithothermodalities
G.D. Chisholm
University Department of Surgery/Urology, Western General
Hospital, Edinburgh EH42XU, UK.
Although it might seem the surgical extirpation of bladder
cancer should be followed by a very good survival rate, the
facts are that this is not necessarily so. Superficial bladder
cancers, 'completely' removed by surgical methods, have
about a 75% 5-year survival rate. Invasive bladder cancers,
'completely' removed by radical excision have about a 35%
5-year survival rate. Thus it is evident that surgery, at best,
can only be part of an overall management strategy. Because
superficial bladder cancer is a multifocal disease, most cases
require additional treatment in the hope of preventing recur-
rence and arresting progression. The management of invasive
bladder cancer remains a frustration because methods for
detecting distant spread are crude. Where selection methods
are optimum then the results of monotherapy may be im-
proved, to a degree, but overall the management of invasive
bladder cancer should now incorporate one of the combina-
tions - surgery/radiotherapy/chemotherapy. Protagonists of
radiotherapy have a long history in UK urology based
mainly on the hope that preservation of the bladder could be832 JOINT WINTER MEETING REPORT
achieved by radiotherapy alone in a high proportion of cases.
A widening range of surgical techniques have led to a reap-
praisal as to whether preservation of the bladder, at all costs,
is now justified.
Chemotherapy forlocally advancedormetastatic transitional
cellcarcinoma-anoverview
G. Mead
Department of Medical Onicology, Royal South Hants
Hospital, Southampton S094PE, UK.
Chemotherapy now has an established role in the manage-
ment of metastatic transitional cell carcinoma (TCC) and a
potential role in the management of locally advanced (T3,
T4) disease. The active chemotherapy drugs cisplatin (C),
methotrexate (M), vinblastine (V), and adriamycin (A), will,
when used as single agents, cause partial regression (PR) in
approximately 15-30% of patients; complete remission (CR)
is however unusual. Initial (though small) randomised trials
have suggested no additional benefit from the use of drug
combinations. In recent years newer drug combinations have
however been devised e.g. CMV and MVAC, which have
been reported as being more effective. This presentation will
discuss the present role of such drug combinations and the
management of this disease emphasising the results of ran-
domised clinical trials, and will detail present and proposed
studies in the UK.
Newdirectionsintreatmentofsuperficial andinvasivebladder
cancer
R.T.D. Oliver, C.J. Gallagher &A. Nouri
Department of Medical Oncology, The Royal London,
London, UK.
The confirmation that long term durable complete remission
can be achieved in greater than 50% of patients with BCG is
increasingly recognised as evidence for the relevance of
immunological response in control of this tumour. Further
evidence in support for this concept will be presented in this
talk which will review results from this department demon-
strating that there is a direct relationship between degree of
loss of HLA class I antigen expression and degree of tumour
invasion as well as the lack of induction of tumour
infiltrating lymphocytes by culture of tumour cell suspensions
with Interleukin-2, suggesting that there may be advantage in
combining BCG with other cytokines that augment HLA
antigen expression. Results from phase lB study of alpha
Interferon in these patients will be presented to illustrate
possible approaches to evaluate such a combination. For
invasive tumours it is increasingly accepted that cisplatin/
methotrexate combinations produce durable complete remis-
sions in patients with metastatic bladder cancer. Review of
patients treated at The Royal London has demonstrated that
frequency of response is highest in patients with lymphatic
spread and lowest in those with blood borne spread particu-
larly ifpositive for BhCG. Tumours that express BhCG have
diminished class I HLA suggesting that they may be harness-
ing immune escape mechanisms similar to those of tropho-
blast. Studies on the doubling time of BhCG positive
tumours and the results from treating poor risk BhCG
positive testis tumours suggests that there could be advant-
ages in alternative drugs schedules and proposals to investi-
gate this possibility will be discussed.
Abstracts of members' proffered
papers
Expression of tyrosinase: a key phenotype marker of
melanocyte differentiation
A.J. Taylor & H. Harris
Sir William Dunn School of Pathology, South Parks Road,
Oxford OX] 3RE.
Tyrosine, the rate-limiting enzyme for melanin synthesis, is a
key phenotypic marker of melanocyte differentiation. In
order to understand better the functions and regulation of
tyrosinase, cell lines expressing tyrosinase in the absence of
all other components of the melanin synthesis pathway have
been established. Mouse 3T3 Swiss fibroblasts, which do not
normally synthesise melanin, were co-transfected by calcium
phosphate precipitation with a G418 resistance marker and a
mouse tyrosinase expression vector, pHDmcTyrl (Muller et
al. (1988). EMBO J., 7, 2723). Of 63 clones isolated, four are
brown in colour, presumably due to synthesis of melanin.
Karyological studies of one clone confirm that it is direct
derivative of the 3T3 Swiss line although there is a
significantly larger number of chromosome fusions in the
transferred cells. The brown clones express both activities of
tyrosinase - tyrosine hydroxylase activity and dopa oxidase
activity - whereas the parent mouse fibroblasts do not. This
confirms that one enzyme, encoded by the cDNA mcTyrl,
has both activities of tyrosinase. Expression of the protein
cannot be detected by Western blot analysis of crude cell
extracts using the anti-tyrosinase monoclonal antibodies
2G10 or TMH-1. Tyrosinase is known to be expressed at a
low level in normal melanocytes (0.01% of total protein) and
the level in transfected cells is probably too low to be
detected by this method. These clones should prove to be
extremely useful in the study of many properties of mouse
tyrosinase, including cofactor requirement, post-translational
modification, and targeting to melanosomes. Understanding
the regulation of this enzyme should provide a starting point
for the elucidation of the mechanism of melanocyte
differentiation.
Cytokine modulationofgelatinaseexpression in aseriesof
humanmelanomacelllines
D.W. Cottamm2, C.Woods', R.A.D. Bunning3, I.G. Rennie2 &
R.C. Rees'
Departments of 'Experimental and Clinical Microbiology,
2Ophthalmology, University of Sheffield Institute for Cancer
Studies and 'Division of Biomedical Science, Sheffield, UK.
The expression of gelatinase (type IV collagenase) in a series
of five human cutaneous (A375, A375 NuPrl, DX3, LT5.1
and SK23) and three human ocular melanoma cell lines
(MEL47, MEL52 and MEL55) and its modulation by
tumour necrosis factor alpha (TNFx) and transforming
growth factor beta (TGFP2) was investigated in vitro. All cell
lines expressed a gelatinase with apparent molecular weight
of 72 kDa, which was both cell associated and secreted into
protein free culture media. Four of the cell lines (A375
NuPrl, DX3, LT5.1 and MEL47) constitutively expressed an
additional gelatinase with an apparent molecular weight of
92 kDa as demonstrated by gelatin zymography. The addi-
tion of TNFx to tumour cells induced the expression of a
92 kDa gelatinase in one cutaneous melanoma cell line
(A375) and one ocular melanoma cell line (MEL55) but had
no modulatory effect on the other cell lines used in this
study. TGFI2 treated tumour cells showed no apparent alter-
ations in their gelatinase secretion patterns. However, co-
incubation of tumour cells with both TNFa and TGFP2
induced production of a 92 kDa gelatinase in SK23 andJOINT WINTER MEETING REPORT 833
MEL52 and an upregulation of the 92 kDa gelatinase in
A375; however, in MEL55 the 72 kDa gelatinase was
upregulated. This study shows that cytokines produced
naturally by host cells (i.e. lymphocytes and/or monocyte/
macrophages) are capable of inducing the expression of a
gelatinase which has previously been associated with tumour
cell variants possessing the metastatic phenotype.
12"'Atl-Methylene blue: targeted radiotherapy fordisseminated
melanoma
E.M. Link' & R,N. Carpenter2
'Department of Chemical Pathology, UCMSM, London;
2Department of Chemistry, Birmingham University, Birming-
ham, UK.
Main difficulties in human melanoma treatment are due to an
early widespread metastatic dissemination. Since melanoma
exhibits variable degree of pigmentation but its entirely non-
pigmented form is uncommon, the presence of melanin in
this neoplasm is exploited in the targeting of cytotoxic
therapy by using radiolabelled methylene blue (MTB) that
binds selectively to this biopolymer. Bio-distribution studies
in vivo revealed the highest and most stable level of MTB in
pigmented melanomas. Further investigations concerning the
anti-melanoma potential of three radioanalogues of the com-
pound: [35S]-MTB, ["251]-MTB and [f"At]-MTB, showed a
significant therapeutic advantage both in vitro and in animal
model system. [2'At]-MTB proved to be the most effective
radioanalogue of MTB: the radioactivity of accumulated
[211At]-MTB in pigmented melanoma cells and needed to
diminish their survival below 4% was two orders of magni-
tude lower than those required of [35S]-MTB and [251I]-MTB.
Present investigations concern human melanoma treatment
with [2"'At]-MTB. The experiments were carried out on
HX34 and HX118 human tumour xenografts transplanted in
nude mice. [21 At]-MTB revealed a therapeutic efficacy as a
scavenger of melanoma cells circulating with blood (number
of lung colonies decreased by more than 95% after a single
intravenous injection of [21'At]-MTB) and in targeted
radiotherapy for solid cutaneous melanoma and lymph node
metastases. Irreversible regression of the cutaneous tumours
was dependent on its size when the treatment was initiated,
its pigmentation and radioactivity of [21'At]-MTB, with frac-
tionation regime significantly more important than a total
dose and a dose per fraction. These results justify introduc-
tion of the treatment to the clinic.
First- andsecond-order drugtargeting tohepaticmelanoma
metastases
L.W. Seymour, K. O'Hare, R. Duncan, J. Strohalm &
K. Ulbrich
CRC Polymer-Controlled Drug Delivery Group, Department of
Biological Sciences, Keele University, Staffordshire ST55BG,
UK.
N-(2-Hydroxypropylmethacrylamide) (HPMA) copolymers
containing doxorubicin (DOX) or melphalan (ME) show
considerable efficacy against many tumours in vivo. Here we
have investigated the effect of liver-targeted and tumour-
targeted drugs on establishment of hepatic metastases in
melanoma-bearing mice. Copolymers were synthesised to
contain ME or DOX (7.6 and 6.9 wt% of drug, respectively).
Liver-targeting was achieved by inclusion of galactosamine
(4.1 mol%) (delivery of the conjugates selectively to
hepatocytes) and tumour-specific targeting was promoted by
incorporation of melanocyte-stimulating hormone (MSH
5.0 mol%). The molecular weight of the conjugates was ap-
proximately 19 kD, polydispersity < 1.4. B16.FIO melanoma
cells (5 x 105) were inoculated into the spleens of male C57
mice. To optimise targeting efficiency all drugs and drug-
conjugates were administered twice daily (I.P, days 1 to 10)
at a dose of 0.5mg drugkg-' body weight. When saline-
treated animals became sick (days 11-12) all mice were killed
and hepatic tumour-invasion was assessed visually and
quantified by assay of melanin. MEL, as free drug,
untargeted or targeted conjugate, showed little inhibition of
tumour metastasis and liver-invasion. DOX, known to be
more active against B16.F10 cells in vitro, also displayed
better efficacy in vivo. Free DOX decreased hepatic invasion
from 30.2 ± 10.3% (control) to 10.2 ± 6.0%. Untargeted
HPMA copolymer-DOX (10.8 ± 3.2%) and galactose-targeted
HPMA copolymer-DOX (10.5 ± 5.0%) gave similar efficacy.
Best was MSH-HPMA copolymer-DOX, which reduced
invasion to 2.0 ± 1.0%. We conclude that tumour-specific
DOX-targeting is more effective than untargeted or organ-
specific therapy in the prevention of liver metastasis of B16
melanoma.
Local tumourdispersalandsolidmodellingofprimary cutaneous
melanoma
J.R. Stretch',2, M.D. Poole', P.R. Millard3, S. Williment4,
J. Simmons4, P.J. Morris2 &A.L. Harris5
Departments of 'Plastic Surgery and 'Histopathology, The
Radcliffe Hospitals, 4IBM UK Scientific Centre, 'Nuffield
Department of Surgery, and 5Clinical Oncology Unit, Univer-
sity of Oxford, UK.
The current surgical treatment of the melanoma primary is
based on apparently reasonable yet essentially indirect data
which suggests that there is an increasing probability of
locally dispersed tumour with biologically more advanced
melanomas. This concept ofthe disease relies heavily on local
recurrence data as conventional histological assessment gives
limited information about the dispersal of tumour within the
wide excision specimen. To obtain direct data describing the
local dispersal of tumour from cutaneous melanoma, a
detailed examination of the entire dermo-epidermis and sub-
jacent tissue excised in the wide surgical treatment of
melanoma has been performed utilising an adjunctive tech-
nique of whole specimen serial horizontal histological
sectioning in combination with tumour detecting immuno-
histochemistry. The wide excision specimens of 25 primary
melanomas has been examined and the pattern of tumour
distribution in these related to the conventional measures of
tumour progression. The serial histological sections of some
of these tumours have been compiled in a solid modelling
computer to produce detailed 3-dimensional reconstructions
of these neoplasms. These reconstructions afford an oppor-
tunity to discern the variation in structural morphology of
primary cutaneous melanoma.
Clinicalandbiologicalresponsesfollowinginterleukin-2 therapy
inpatients withmetastatic melanomaandrenalcell carcinoma
M.S. Dorreen', E. Sheridan', T. Sreenivasan', K. Hayat',
S. Rogers', L. Bruce', B.W. Hancock', K. Chapman2&
R.C. Rees2
'Department of Clinical Oncology, 'Department Experimental
Microbiology, Sheffield University, UK.
In a phase II clinical study, six patients (pts): four male, two
female, median age 60 years, with metastatic melanoma,
completed therapy with DTIC and interleukin-2 (IL-2). This
comprised: DTIC at 250 mg m2 IV x 5 days and IL-2 at
3 x 106 U m-2 24 h-' given as two 5-day IV infusions star-
ting 16 days after DTIC. After a 1-week gap, at least one
further course was given. Major responses were seen in two
(33%) pts, both female, aged 60 and 65, who achieved com-
plete and partial remission (CR, PR), respectively. Both834 JOINT WINTER MEETING REPORT
remain free of progression at >7 months after therapy. One
additional pt remains well with stable disease at >7 months.
Three pts are dead of progressive melanoma. Five other pts
with melanoma: three female, two male, median age 44,
received r-IFN-a 2a at 3 x 106 U m 2 by subcutaneous injec-
tion x 5 days, followed by IL-2, as above. This was repeated
at least once, after a 16-day gap. All pts suffered progressive
disease and four have died. Nine pts with metastatic renal
cell carcinoma (RCC): five male, four female, median age 55,
received IL-2 alone, as described above. At least three cycles
at 16-day intervals, were given. There were no major res-
ponses, but 2 pts remain well with stable disease at >2
months from therapy. Two pts have died of RCC. Treatment
was well tolerated although the one pt with melanoma, who
attained PR, developed hypothyroidism. Twelve pts have
been monitored for immune responses. All developed
augmented natural killer (NK) and lymphokine-activated
killer (LAK) cell activity. Increased lymphocyte proliferation
was invariable and, in the 2nd week of each cycle,
eosinophilia developed. IL-2 did not stimulate the production
of tumour necrosis factor (TNF) although in one pt with
RCC and bony involvement, there was evidence of enhanced
endogenous production of TNF. Production of soluble IL-2
receptors was observed and IL-6 production was stimulated
in the 2nd week of IL-2 therapy. While there was no clear
correlation between clinical response and bio-immunological
activity, the highest levels of IL-6 were observed in the one,
female pt with melanoma, who achieved CR. These high
levels have been maintained during the current period in
which she remains free of detectable relapse.
Anewmonoclonal antibody totransitionalcell carcinoma
R.C. Kockelbergh"2, E.B. Austin', M.R. Price', R.W. Baldwin'
& M.C. Bishop2
'Cancer Research Campaign Laboratories, University of
Nottingham, 2Department of Urology, City Hospital, Notting-
ham, UK.
Many monoclonal antibodies prepared by immunisation with
bladder cancer cell lines, do not appear to recognise primary
bladder tumour tissue. Our aim was to produce a specific
antibody to transitional cell carcinoma (TCC) using primary
tumour as an immunogen. Balb/c mice were immunised with
a disaggregated primary bladder tumour on two occasions
followed by boosting with a second tumour 4 days prior to
fusion with P3NSI. We have produced an antibody 977 3B2
which stained six to nine bladder tumours and none of five
normal bladders so far tested by immunohistology. 977 3B2
binds to cytoplasmic granules and cell membrane, and reacts
with antigens expressed upon the bladder cell line RT112, but
not the cell lines Colo 205 or 791T. By immunohistology the
determinant has not been identified in a variety of normal
tissues. The reactivity of 977 3B2 with tissue specimens (nor-
mal and malignant including non TCC tumours) is presently
under extensive investigation.
Measurement ofthein vivoproliferationkineticsofurothelial
tumoursbymultiparameter flowcytometry
D.A. Rew, D. Thomas, M.J. Coptcoat&G.D. Wilson
Department of Surgery and Urology, St Mary's Hospital,
Portsmouth; The Gray Laboratory, The Cancer Research
Campaign, UK.
The in vivo labelling of urological tumour cells using the S
phase marker bromodeoxyuridine (BRdU) has been reported.
The use of multiparameter flow cytometry (FCM) with
BRdU labelling to study tumour proliferation provides
simultaneous measurements of the DNA ploidy (DI), the
duration of the S phase (Ts), the potential doubling time
(Tpot) and the total and aneuploid tumour labelling indices
(LI) from a single specimen. Heterogenous tumour cell
populations can be measured with high sensitivity. We report
a study to evaluate the method in the measurement of the
kinetics oftransitional cell carcinoma ofthe bladder (TCCB).
Eleven patients with a proven TCCB consented to receive a
bolus dose of 250 mg BRdU 3-6 h prior to endoscopic
tumour resection. Multiparameter FCM analysis of ethanol
preserved tissue was performed using propidium iodide to
measure DNA content and a monoclonal antibody to detect
BRdU incorporated into S phase nuclei. One tumour was
aneuploid, DI = 1.89. The remainder were diploid. BRdU
uptake was detected in all tumours. The median LI was
2.5%, range 0.3-4.6%. In 7/11 tumours the profile was
satisfactory for calculation of the Ts and Tpot. The mean Ts
was 6.0 h (range 3.5-9.7) and the mean Tpot was 25.8 days
(range 5.3-64.8). This study demonstrates that measurement
of urothelial tumour proliferation in vivo is possible. These
parameters are being assessed in a continuing study of a
variety of urological tumours as indices of tumour recur-
rence, therapy and clinical prognosis.
p53,c-erbB-2 andEGFrinbladdercancer
K. Mellon', C. Wright2, J. Lunec3, A.L. Harris5, D.P. Lane4,
C.H.W. Home2 & D.E. Neal'
Departments of 'Surgery/Urology, 2Pathology and 3Cancer
Research Unit, University of Newcastle upon Tyne; 'ICRF,
Potter's Bar, Hertfordshire; 51nstitute of Molecular Medicine,
John Radcliffe Hospital, Oxford, UK.
Recent studies have suggested that altered expression of the
p53 gene is a common abnormality in colo-rectal and lung
cancer and increased amounts of epidermal growth factor
receptor protein (EGFr) are found in locally advanced blad-
der cancer. We recently described altered expression of
c-erbB-2 in bladder cancer and have carried out this study to
determined the relationship between these three oncoproteins.
Expression of the p53, EGFr and c-erbB-2 protein was
studied in 82 patients with primary bladder cancer using an
immunohistochemical method. Strong staining was found in
17% of tumours for p53, in 15% for c-erbB-2 and in 30%
for the EGFr. Tumours invading bladder muscle were more
likely to be positively stained for p53 and EGFr compared
with superficial tumours. No association was found between
p53 and EGFr expression, but there was a positive correla-
tion between the expression ofc-erbB-2 and p53. No associa-
tion was found between muscle invasive tumours and
increased expression of c-erbB-2. Analysis of DNA by
Southern transfer hybridisation revealed one case of c-erbB-2
gene amplification from 27 samples examined. This tumour
was one of the two strongest positively staining samples in
the immunohistochemistry series. Elevated levels of c-erbB-2
transcripts were detected in four out of 50 RNA samples
screened. Alteration in the expression of p53, EGFr and
c-erbB-2 were found frequently in human transitional cell
carcinoma of the urinary bladder and may be of clinical use
in defining patients with differing prognosis.
TGF-o/EGFlevelsinbladdercancerandtheirrelationshipto
EGFr
K. Mellon',2, S. Cook2, P. Chambers2 & D.E. Neal" 2
'Urology Department, Freeman Hospital, Newcastle upon
Tyne NE7 7DN, and 2University Department of Surgery,
University of Newcastle upon Tyne, UK.
We have already shown that a significant proportion of
bladder cancers overexpress the epidermal growth factor
receptor protein (EGFr). Both EGF and Transforming
Growth Factor-alpha (TGF-a) are known ligands for theJOINT WINTER MEETING REPORT 835
EGFr. Evidence suggests that EGF has an exocrine function
with high levels in body fluids, whereas TGF-a may be more
important at tissue level where it could function through
either autocrine or paracrine mechanisms. We have deter-
mined the levels of EGF and TGF-x in 47 bladder specimens
(including 40 bladder tumours) by radioimmunoassay. EGFr
content was also determined using a radioligand binding
assay. Significantly higher levels of TGF-a (Mean ± s.d.
8.47 ± 9.81 ng gm-') were detected compared with EGF
(0.82 ± 0.94 ng gm-1). In addition, higher levels of TGF-a
were detected in malignant (9.50 10.26 ng gm') compared
with non-malignant tissue (2.60 2.49 ng gm-). There did
not appear to be any correlation between ligand level and
EGFr content or between ligand level and tumour stage or
grade. The previously reported association of EGFr content
and tumour stage and grade was again evident. These results
strengthen the argument in favour of TGF-a being the more
important ligand at tissue level. Whether high TGF-a levels
have a significant impact on the biological behaviour of these
tumours will be determined by clinical follow up.
Ectopicsecretionof1-HCG by bladdercancers-aclinical
markerofmetastasis andprognosis
R.K. Iles &T. Chard
Department of Reproductive Physiology, St Bartholomew's
Hospital Medical College, London ECIA 7BE, UK.
Though previously considered to be a marker of the ex-
tremely rare chorioepithelioma of the bladder, immunoreac-
tive hCG-like material can be detected in serum in 30% of
bladder patients. It has been shown in vitro that seven of
nine bladder tumours and four of five urothelial cell lines
secrete hCG-like material into their culture media (Iles et al.,
1987). Immunochemical analysis showed that this material
consisted almost entirely of free a-subunit (Iles & Chard,
1989). Serum and early morning urine samples from 175
patients, with various stages of bladder disease, were assayed
for hCG using a P-subunit, directed RIA. Forty-six patients
showed elevated levels. Elevated levels of serum immunoreac-
tive P-hCG was detected in 16 of 21 patients (76%) with
confirmed metastases, but only two of 64 patients (3%) with
disease limited to the pelvis. In urine elevated P-hCG levels
were detected in 14 of 57 TA/I cases (25%), 11 of 25 T2/T4
cases (71%) and five of seven metastatic disease patients
(71%) (Iles et al., 1989). Immunochemical analysis of sam-
ples from this study showed that only one of seven metastatic
patients and one of 21 patients with disease limited to the
bladder, produced intact hCG. Since only the intact hCG a-P
hetrodimer is biologically active; this explains the discrepancy
between the high incidence of immunoreactive hCG expres-
sion by bladder tumours and the rarity of gonadotrophin
associated clinical endocrinopathies (Iles et al., 1990).
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